Drug Price Trends for GNP MUCUS RLF SINUS CONG PAIN

Average Pharmacy Cost for GNP MUCUS RLF SINUS CONG PAIN

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
GNP MUCUS RLF SINUS CONG PAIN	46122-0712-60	0.11505	EACH	2025-05-21
GNP MUCUS RLF SINUS CONG PAIN	46122-0712-60	0.11488	EACH	2025-04-23
GNP MUCUS RLF SINUS CONG PAIN	46122-0712-60	0.11197	EACH	2025-03-19
GNP MUCUS RLF SINUS CONG PAIN	46122-0712-60	0.11405	EACH	2025-02-19
GNP MUCUS RLF SINUS CONG PAIN	46122-0712-60	0.11364	EACH	2025-01-22
GNP MUCUS RLF SINUS CONG PAIN	46122-0712-60	0.11597	EACH	2024-12-18

Market Analysis and Price Projections for GNP MUCUS RELIEF SINUS CONG PAIN: A Comprehensive Overview

Introduction to Guaifenesin

Guaifenesin, the active ingredient in GNP MUCUS RELIEF SINUS CONG PAIN, is an expectorant widely used to help clear mucus and phlegm from the airways, making breathing easier. It is a key component in various cough and cold medications.

Global Guaifenesin Market Overview

The global guaifenesin market is projected to reach USD 95 million by 2027, growing at a Compound Annual Growth Rate (CAGR) of approximately 3.1% from 2022 to 2027. This growth is driven by increasing demand for respiratory health management, particularly post-pandemics like COVID-19[1].

Market Segmentation

By Application

The cough treatment drug segment is the fastest-growing segment in the guaifenesin market, expected to grow at a CAGR of around 3.7% during the forecast period. Guaifenesin is used in various forms such as syrups, tablets, dissolving granules, and extended-release tablets, catering to pediatric and geriatric age groups[4].

By Geography

North America is the fastest-growing region in the global guaifenesin market, with a CAGR of around 4.5% during the forecast period. The high demand in this region is influenced by the development in the pharmaceutical sector and the growing need for respiratory health management[4].

Demand Drivers

Growing Applications in Cough Treatment

The increasing application of guaifenesin in cough treatment drugs, particularly in hospitals and clinics, is a significant driver. The Indian pharmaceutical sector, for example, is expected to reach USD 65 billion by 2024 and around USD 120-130 billion by 2030, further boosting the demand for guaifenesin[1][4].

Increasing Consumer Interest in Oral Medications

Consumer interest in oral medications, including expectorants, contributes to the demand. China, with its reliance on traditional Chinese medicine and high incidence of respiratory diseases, is a key market[1].

Advancements in Hospital Infrastructure and Technology

Robust advancements in hospital infrastructure and innovations in drug delivery and processing projects are also driving the growth of the guaifenesin market. These advancements enhance the efficacy and appeal of guaifenesin-based products[4].

Price Projections and Market Dynamics

Raw Material Costs

Fluctuations in the cost of glycerin and guaiacol, the raw materials used to produce guaifenesin, can impact the final product price. These costs can vary based on market conditions and supply chain stability[1].

Regulatory Environment

Changes in regulatory standards related to pharmaceutical manufacturing and safety can affect production costs and subsequently prices. Compliance with these regulations is crucial for maintaining market presence[1].

Market Competition

The presence of substitutes and the overall competitive landscape in the expectorant drugs market can influence pricing strategies. Companies must balance pricing with the need to remain competitive while ensuring profitability[1].

Challenges and Opportunities

Availability of Substitutes

The global guaifenesin market faces challenges from the availability of substitute expectorants, which can impact market share and pricing. However, innovations in drug delivery and processing can enhance the efficacy and appeal of guaifenesin-based products, potentially leading to higher demand and stable or increasing prices[1].

Technological Advancements

Technological advancements in drug delivery and processing can enhance the efficacy and appeal of guaifenesin-based products. These innovations can lead to higher demand and stable or increasing prices, providing opportunities for market growth[1].

Regional Market Analysis

North America

The North American market, particularly the U.S., sees significant demand for guaifenesin due to high hospital drug expenses. According to the American Hospital Association, hospital drug expenses per adjusted discharge increased by 30.3% in 2020-21 compared to 2019[1].

Asia-Pacific

China is a key market with an anticipated CAGR of 8.1% for expectorant drugs by 2034. The country's healthcare system, which includes traditional Chinese medicine, drives the demand for expectorant herbs and medications[1].

Impact of COVID-19

The COVID-19 pandemic had a significant impact on the global guaifenesin market. Initially, the pandemic led to disruptions in supply chains, production halts, and lockdown restrictions, affecting the availability of medications. However, the surging production and demand for cough and cold medications in the recovery phase led to major growth opportunities in the market. Medicaid spending increased by 9.2% to USD 671.2 billion in 2020, and hospital spending saw a 6.4% increase in the U.S., further boosting the demand for guaifenesin[4].

Product Specifics: GNP MUCUS RELIEF SINUS CONG PAIN

Product Description

GNP MUCUS RELIEF SINUS CONG PAIN is a sustained-release formulation of guaifenesin, designed to provide extended relief from sinus congestion and cough. It is available in various forms, including tablets and syrups, making it accessible to a wide range of patients[2].

Pricing

The price of GNP MUCUS RELIEF SINUS CONG PAIN can vary based on several factors, including raw material costs, regulatory environment, and market competition. As of recent data, a 20-count pack of GNP MUCUS RELIEF ER 600MG TAB is priced around $12.99[2].

Side Effects and Precautions

Common side effects of guaifenesin include nausea or vomiting. Serious allergic reactions are rare but can include symptoms such as rash, itching, severe dizziness, and trouble breathing. Patients should discuss their medical history, especially breathing problems, with their doctor before using this medication[2].

Key Takeaways

• Cough Treatment Segment Growth: The cough treatment drug segment is the fastest-growing segment in the guaifenesin market, expected to grow at a CAGR of around 3.7% during the forecast period[4].
• Multispecialty Hospitals: Multispecialty hospitals are the largest end-users of guaifenesin, holding over 57% of the global market share in 2021[1].
• Regional Market Growth: Regional markets, especially in Asia-Pacific, are driving growth due to traditional medicine practices and high incidence of respiratory diseases[1].
• Technological Advancements: Innovations in drug delivery and processing are enhancing the efficacy and appeal of guaifenesin-based products, leading to higher demand and stable or increasing prices[1].

FAQs

1. What is the projected market size of the global guaifenesin market by 2027?

The global guaifenesin market is forecasted to reach USD 95 million by 2027[1].

2. Which segment is the fastest-growing in the guaifenesin market?

The cough treatment drug segment is the fastest-growing, expected to grow at a CAGR of around 3.7% during the forecast period[4].

3. What is the significance of the multispecialty hospital segment in the guaifenesin market?

The multispecialty hospital segment held the largest market share in 2021, with over 57% of the global guaifenesin market[1].

4. How does the broader expectorant drugs market impact guaifenesin-based products?

The expectorant drugs market, valued at USD 17,648.2 million in 2024, is projected to reach USD 38,455.4 million by 2034, driving demand for guaifenesin-based products like GNP MUCUS RELIEF SINUS CONG PAIN[1].

5. What are the key drivers of the guaifenesin market?

Key drivers include growing applications in cough treatment drugs, increasing consumer interest in oral medications, and advancements in hospital infrastructure and technology[1][4].

Sources

1. DrugPatentWatch - Market Analysis and Financial Projection for Guaifenesin-Based Drugs[1].
2. Davis Islands Pharmacy - GNP MUCUS RELIEF ER 600MG TAB 20CT[2].
3. Business Research Insights - Sinusitis Medicine Market Size and Global Forecast[3].
4. IndustryARC - Guaifenesin Market Size Report, 2022-2027[4].

Last updated: 2025-01-07